| Dr Susan B Upham, MD, MPH | |
|
323 Marginal Way, Portland, ME 04101-2543 | |
| (207) 780-6631 | |
| (207) 780-6320 |
| Full Name | Dr Susan B Upham |
|---|---|
| Gender | Female |
| Speciality | Preventive Medicine - Occupational Medicine |
| Location | 323 Marginal Way, Portland, Maine |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265565683 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2083X0100X | Preventive Medicine - Occupational Medicine | 013905 (Maine) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Susan B Upham, MD, MPH 34 Rivers Edge Dr, Kennebunk, ME 04043-7742 Ph: (207) 967-4835 | Dr Susan B Upham, MD, MPH 323 Marginal Way, Portland, ME 04101-2543 Ph: (207) 780-6631 |
News Archive
Ben-Gurion University of the Negev (BGU) researchers have developed a unique technology that stabilizes an otherwise unstable form of calcium carbonate. This mineral form provides significantly higher biological absorption and retention rates than other sources presently used as dietary calcium supplements.
In about half of all prostate tumours, there are two genetic areas that are fused with one another. When this is not the case, the exact way cancer cells originate in prostate tumours was not clear until now.
Plans are afoot next year for British surgeons to attempt to make the first repairs of spinal cord nerves using a revolutionary new stem cell technique.
Ember Therapeutics, Inc., a company harnessing breakthroughs in brown fat biology and insulin sensitization to revolutionize the treatment of metabolic disease, today announced the publication of key preclinical data demonstrating that inhibition of the Transient Receptor Potential Vanilloid (TRPV) family of ion channels - specifically TRPV4 - resulted in activation of brown/beige fat and protection from diet-induced obesity, inflammation and insulin resistance. Ember holds an exclusive option to license these TRPV4 findings and technology.
Ipsen (Paris:IPN), an innovation-driven global specialty pharmaceutical group, today announced that its partner Roche has disclosed the results of a first phase III clinical study using Taspoglutide, the first human once weekly glucagon-like peptide-1 (GLP-1) analogue originating from Ipsen's Research.
› Verified 6 days ago
Deborah S. Rojas, RN Preventive Medicine Medicare: Not Enrolled in Medicare Practice Location: 54 Saint John St, Portland, ME 04102 Phone: 123-456-7890 | |
Richard J Maguire, M.D. Preventive Medicine Medicare: Not Enrolled in Medicare Practice Location: 1600 Congress St, Portland, ME 04102 Phone: 207-774-7751 Fax: 207-828-5140 | |
Dr. David W Dickison, D.O. Preventive Medicine Medicare: Not Enrolled in Medicare Practice Location: 22 Bramhall Street, Portland, ME 04102 Phone: 207-662-4011 Fax: 207-662-6392 | |
Alan Norton Weiner, D.O. Preventive Medicine Medicare: Not Enrolled in Medicare Practice Location: 4 Milk St, Portland, ME 04101 Phone: 207-828-8080 Fax: 207-828-6816 | |
Sylvia Park, MD Preventive Medicine Medicare: Medicare Enrolled Practice Location: 53 Baxter Blvd Ste 3, Portland, ME 04101 Phone: 207-613-4115 |